IP Library Granted Patent US 10,441,588
Granted Patent B2
US 10,441,588 · App. 15/711,648 · Granted Oct 15, 2019

Methods and compositions for treating bacterial infection

Inventors: Hongmin Sun (Columbia, MO); David W. Anderson (Columbia, MO); Feng Qi (Columbia, MO)
Assignees: Curators of the University of Missouri; Nanova, Inc.
A61K31/517A61K9/0014A61K31/505A61K31/519A61K31/527A61K31/5377A61K45/06A61K47/06A61K47/44A61L27/54A61L29/16A61L31/16A61L2300/404Y02A50/473
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,441,588
App. No.
15/711,648
Granted
Oct 15, 2019
Kind
B2
Abstract

The present disclosure relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present disclosure provides compounds as therapeutic agents against bacterial infections (e.g., biofilms). The present disclosure also provides topical formulations for use in methods for treating bacterial infections.

Claims (17)

1. A topical formulation for treating a bacterial infection comprising:

a compound having the structure of Formula V

wherein X is SR 1 , NH 2 , NHR 1 , NR 1 R, OH, OR 1 , or Cl; wherein R and R 1 are, independently, H, a C1-C8 alkyl or alkenyl or cycloalkyl, optionally substituted with F, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl or heteroaryl, wherein one or more alkyl carbons may be replaced by O; R 2 is H or a Cl alkyl; R 3 and R 4 are, independently, a C1-C8 alkyl; R 5 is C1-C6 alkyl, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl, heteroaryl, SO 2 R 6 , NHCOR 6 , SO 2 NHR 6 , or OCOR 6 ; R 6 is H, C1-C6 alkyl, C0-C3 alkyl-aryl, or C0-C3 alkyl-heteroaryl, all optionally substituted; and R 11 is H or a C1 alkyl; and

a base comprising a hydrocarbon base, an oil, and combinations thereof.

2. The topical formulation of claim 1 , wherein the compound is selected from the group consisting of:

and combinations thereof.

3. The topical formulation of claim 1 comprising about 0.05 wt. % to about 5.0 wt. % of the compound having the structure of Formula V.

4. The topical formulation of claim 1 , wherein the hydrocarbon base comprises liquid paraffin, white petrolatum, a wax, esters of fatty alcohols, saturated fatty acids, oleic acid, olive oil, starch glycerin, purified lanolin, cetyl alcohol, glyceryl monostearate, methylparaben, propylparaben, glycol ethers, gelation hydrocarbon, polyethylene glycol, polyoxyl 40 stearate, polysorbates, hydrophilic ointment base, ceresine, white ointment base, absorptive ointment base, Macrogol ointment base, simple ointment base, beeswax, wool fat, mineral oil, and combinations thereof.

5. The topical formulation of claim 1 , wherein the oil comprises a vegetable oil.

6. A topical formulation for treating a bacterial infection comprising:

a compound having the structure of Formula V

wherein X is SR 1 , NH 2 , NHR 1 , NR 1 R, OH, OR 1 , or Cl; wherein R, R 1 and R 2 are, independently, H, a C1-C8 alkyl or alkenyl or cycloalkyl, optionally substituted with F, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl or heteroaryl, wherein one or more alkyl carbons may be replaced by O; R 3 and R 4 are, independently, a C1-C8 alkyl; R 5 is H, C1-C6 alkyl, CN, OR 6 , NR 6 2 , COR 6 , CO 2 R 6 , CONHR 6 , aryl, heteroaryl, SO 2 R 6 , NHCOR 6 , SO 2 NHR 6 , or OCOR 6 ; R 6 is H, C1-C6 alkyl, C0-C3 alkyl-aryl, or C0-C3 alkyl-heteroaryl, all optionally substituted; and R 11 is H or a Cl alkyl; and

a base comprising a vegetable oil,

wherein the formulation is a topical formulation.

7. The topical formulation of claim 6 , wherein the compound is selected from the group consisting of:

and combinations thereof.

8. The topical formulation of claim 6 comprising about 0.05 wt. % to about 5.0 wt. % of the compound having the structure of Formula V.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2019
From: ANDERSON, DAVID W.
To: NANOVA, INC.
Reel/Frame 048108/0038 →
CONFIRMATORY LICENSE Recorded Feb 12, 2018
From: UNIVERSITY OF MISSOURI-COLUMBIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045307/0355 →
Continuity (4)
Continuation In Part 15335156 · Oct 26, 2016
Continuation In Part 14397798
Provisional Application 61641590 · May 2, 2012
Related Publication 20180042928A1 · Feb 15, 2018